Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design
Identifieur interne : 006213 ( Main/Exploration ); précédent : 006212; suivant : 006214Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design
Auteurs : Jim Zhen Wu [États-Unis] ; Chin-Chung Lin [États-Unis] ; Zhi Hong [États-Unis]Source :
- Journal of Antimicrobial Chemotherapy [ 0305-7453 ] ; 2003.
English descriptors
- Teeft :
- Active site, Adenosine, Adenosine deaminase, Antimicrobial, Antimicrobial agents, Antimicrobial chemotherapy, Antiviral, Antiviral activity, Antiviral chemistry, Article figure, Catalysis, Catalytic efficiency, Cell culture, Chemotherapy, Combination therapy, Consecutive deamination reactions, Deaminase, Deamination, Dioxolane, Haemolytic anaemia, Hydrogen bond, Hydrolytic deamination, Inactive metabolite, Inosine, Medicinal chemistry, Multiple conformations, Mutation, Nucleoside, Pharmacokinetic, Poliovirus, Prodrug, Prodrugs, Purine, Rbc, Ribavirin, Ribonucleoside, Ribonucleosides, Ribose, Single mutation, Specific interactions, Substrate recognition, Viral, Viramidine, Water molecule.
Url:
DOI: 10.1093/jac/dkg405
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001643
- to stream Istex, to step Curation: 001643
- to stream Istex, to step Checkpoint: 002216
- to stream Main, to step Merge: 006718
- to stream Main, to step Curation: 006213
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design</title><author><name sortKey="Wu, Jim Zhen" sort="Wu, Jim Zhen" uniqKey="Wu J" first="Jim Zhen" last="Wu">Jim Zhen Wu</name></author><author><name sortKey="Lin, Chin Chung" sort="Lin, Chin Chung" uniqKey="Lin C" first="Chin-Chung" last="Lin">Chin-Chung Lin</name></author><author><name sortKey="Hong, Zhi" sort="Hong, Zhi" uniqKey="Hong Z" first="Zhi" last="Hong">Zhi Hong</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E5C7195F9783AC578D4DCB5632D93373D1BA0AD7</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1093/jac/dkg405</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-QVM6N2HT-2/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001643</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001643</idno><idno type="wicri:Area/Istex/Curation">001643</idno><idno type="wicri:Area/Istex/Checkpoint">002216</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002216</idno><idno type="wicri:doubleKey">0305-7453:2003:Wu J:ribavirin:viramidine:and</idno><idno type="wicri:Area/Main/Merge">006718</idno><idno type="wicri:Area/Main/Curation">006213</idno><idno type="wicri:Area/Main/Exploration">006213</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design</title><author><name sortKey="Wu, Jim Zhen" sort="Wu, Jim Zhen" uniqKey="Wu J" first="Jim Zhen" last="Wu">Jim Zhen Wu</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Drug Discovery and Development, Ribapharm Inc., 3300 Hyland Avenue, Costa Mesa, CA 92626</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Drug Discovery and Development, Ribapharm Inc., 3300 Hyland Avenue, Costa Mesa, CA 92626</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Lin, Chin Chung" sort="Lin, Chin Chung" uniqKey="Lin C" first="Chin-Chung" last="Lin">Chin-Chung Lin</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Drug Discovery and Development, Ribapharm Inc., 3300 Hyland Avenue, Costa Mesa, CA 92626</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Hong, Zhi" sort="Hong, Zhi" uniqKey="Hong Z" first="Zhi" last="Hong">Zhi Hong</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Drug Discovery and Development, Ribapharm Inc., 3300 Hyland Avenue, Costa Mesa, CA 92626</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Antimicrobial Chemotherapy</title><title level="j" type="abbrev">J. Antimicrob. Chemother.</title><idno type="ISSN">0305-7453</idno><idno type="eISSN">1460-2091</idno><imprint><publisher>Oxford University Press</publisher><date type="published">2003</date><biblScope unit="vol">52</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="543">543</biblScope><biblScope unit="page" to="546">546</biblScope></imprint><idno type="ISSN">0305-7453</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0305-7453</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Active site</term><term>Adenosine</term><term>Adenosine deaminase</term><term>Antimicrobial</term><term>Antimicrobial agents</term><term>Antimicrobial chemotherapy</term><term>Antiviral</term><term>Antiviral activity</term><term>Antiviral chemistry</term><term>Article figure</term><term>Catalysis</term><term>Catalytic efficiency</term><term>Cell culture</term><term>Chemotherapy</term><term>Combination therapy</term><term>Consecutive deamination reactions</term><term>Deaminase</term><term>Deamination</term><term>Dioxolane</term><term>Haemolytic anaemia</term><term>Hydrogen bond</term><term>Hydrolytic deamination</term><term>Inactive metabolite</term><term>Inosine</term><term>Medicinal chemistry</term><term>Multiple conformations</term><term>Mutation</term><term>Nucleoside</term><term>Pharmacokinetic</term><term>Poliovirus</term><term>Prodrug</term><term>Prodrugs</term><term>Purine</term><term>Rbc</term><term>Ribavirin</term><term>Ribonucleoside</term><term>Ribonucleosides</term><term>Ribose</term><term>Single mutation</term><term>Specific interactions</term><term>Substrate recognition</term><term>Viral</term><term>Viramidine</term><term>Water molecule</term></keywords></textClass></profileDesc></teiHeader></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Wu, Jim Zhen" sort="Wu, Jim Zhen" uniqKey="Wu J" first="Jim Zhen" last="Wu">Jim Zhen Wu</name></region><name sortKey="Hong, Zhi" sort="Hong, Zhi" uniqKey="Hong Z" first="Zhi" last="Hong">Zhi Hong</name><name sortKey="Lin, Chin Chung" sort="Lin, Chin Chung" uniqKey="Lin C" first="Chin-Chung" last="Lin">Chin-Chung Lin</name><name sortKey="Wu, Jim Zhen" sort="Wu, Jim Zhen" uniqKey="Wu J" first="Jim Zhen" last="Wu">Jim Zhen Wu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006213 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006213 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E5C7195F9783AC578D4DCB5632D93373D1BA0AD7
|texte= Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design
}}
| This area was generated with Dilib version V0.6.33. |  |